PTC Therapeutics, Inc. (NASDAQ:PTCT) is set to release its earnings data after the market closes on Tuesday, October 31st. Analysts expect PTC Therapeutics to post earnings of ($0.48) per share for the quarter.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.45. PTC Therapeutics had a negative net margin of 88.43% and a negative return on equity of 81.84%. The firm had revenue of $47.96 million during the quarter, compared to the consensus estimate of $28.78 million. During the same period in the prior year, the firm earned ($1.14) EPS. The business’s revenue was up 206.9% on a year-over-year basis. On average, analysts expect PTC Therapeutics to post $-2.51 EPS for the current fiscal year and $-2.53 EPS for the next fiscal year.

Shares of PTC Therapeutics, Inc. (PTCT) traded down 1.94% during mid-day trading on Tuesday, reaching $16.66. 159,114 shares of the company’s stock were exchanged. PTC Therapeutics, Inc. has a 52-week low of $4.03 and a 52-week high of $22.00. The stock’s market cap is $689.54 million. The stock’s 50-day moving average is $19.13 and its 200-day moving average is $16.93.

Several equities analysts have commented on the stock. BidaskClub downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. William Blair assumed coverage on shares of PTC Therapeutics in a research report on Wednesday, August 23rd. They issued a “market perform” rating and a $17.00 target price for the company. J P Morgan Chase & Co reissued a “neutral” rating and issued a $21.00 target price (up previously from $15.00) on shares of PTC Therapeutics in a research report on Friday, June 30th. Barclays PLC reduced their target price on shares of PTC Therapeutics from $22.00 to $15.00 and set an “equal weight” rating for the company in a research report on Friday, September 29th. Finally, Zacks Investment Research raised shares of PTC Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. PTC Therapeutics has an average rating of “Hold” and a consensus target price of $17.11.

TRADEMARK VIOLATION NOTICE: “PTC Therapeutics, Inc. (PTCT) to Release Earnings on Tuesday” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Earnings History for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with's FREE daily email newsletter.